Citations

Clear

4847 citation(s) found for "Yu, Eric".

Abstract 112: Use of Evidence-Based Therapies in the Treatment of Cardiovascular Comorbidities and Risk Factors in Patients with Atrial Fibrillation: Findings From the ORBIT-AF Registry
Hess, Paul L. , Kim, Sunghee , Piccini, Jonathan P. , Chang, Paul, Ansell, Jack , Go, Alan S. , Allen, Larry A. , Gersh, Bernard J. , Hylek, Elaine M. , Mahaffey, Kenneth W. , Freeman, James V. , Peterson, Eric D. , Fonarow, Gregg C.

Mayo Clinic

Circulation: Cardiovascular Quality and Outcomes | December 8, 2021 | Volume: 5 | Issue: suppl_1 | Pages: No page available

10.1161/circoutcomes.5.suppl_1.a112 Get It

Background: The use of evidence-based therapies to treat cardiovascular comorbidities and risk factors in patients with AF in outpatient clinical practice has not been well characterized. Methods: Using a large, community-based registry of patients with AF in the United States, the prevalence of cardiovascular comorbidities and corresponding use of evidence-based therapies were determined. Results: Among 9,589 enrolled patients with AF, the median age was 75 years; 57.8% were male; 10.7% were non-white; 69.9% had Medicare or Medicaid; 31.8% had coronary heart disease, 32.2% had heart failure, 13.0% had peripheral vascular disease, and 29.5% had diabetes mellitus. Among eligible patients, 62.8% of 3,612 were prescribed an antiplatelet agent, 72.1% of 4,674 were prescribed a β-blocker, 59.7% of 5,121 were prescribed an angiotensin converting enzyme inhibitor or angiotensin receptor blocker, 15.7% of 624 were prescribed an aldosterone antagonist, 70.1% of 6,914 were prescribed a statin, 94.7% of 8,329 were prescribed an antihypertensive, 58.3% of 504 had an ICD, and 44.5% of 9,589 received all indicated evidence-based therapies ( Table ). Conclusion: Cardiovascular comorbidities and risk factors in patients with AF are often inadequately treated with evidence-based therapies in the outpatient practice setting, underscoring opportunities to improve care for patients with AF.
The protective gene dose effect of the APOEε2 allele on gray matter volume in cognitively unimpaired individuals
Salvadó, Gemma , Ferreira, Daniel , Operto, Grégory , Cumplido‐Mayoral, Irene , Falcón, Carles , Vilor‐Tejedor, Natàlia , Minguillón, Carolina , Groot, Colin , Barkhof, Frederik , Scheltens, Philip , Ossenkoppele, Rik , Kern, Silke , Zettergren, Anna , Hort, Jakub , Stomrud, Erik , Westen, Danielle van , Hansson, Oskar , Westman, Eric , Gispert, Juan Domingo , ADNI, ALFA study†, BioFINDER,, Crous‐Bou, Marta , Arenaza-Urquijo, Eider M , Cacciaglia, Raffaele , Falcon, Carles , Vilor-Tejedor, Natàlia , Minguillon, Carolina , Groot, Colin , van der Flier, Wiesje M , Barkhof, Frederik , Scheltens, Philip , Ossenkoppele, Rik , Skoog, Ingmar , Stomrud, Erik , van Westen, Danielle , Hansson, Oskar , Molinuevo, José Luis , Wahlund, Lars-Olof , Westman, Eric , Gispert, Juan Domingo , Ferreira, Daniel , Hort, Jakub , Arenaza‐Urquijo, Eider M. , Flier, Wiesje M. van der , Skoog, Ingmar , Molinuevo, José Luís , Wahlund, Lars‐Olof , ADNI, ALFA study†, BioFINDER,

Mayo Clinic

Alzheimer's & Dementia | December 8, 2021 | Volume: 18 | Issue: 7 | Pages: 1383-1395

10.1002/alz.12487 | PMID 34877786 Get It

AbstractIntroductionHarboring two copies of the apolipoprotein E (APOE) ε2 allele strongly protects against Alzheimer's disease (AD). However, the effect of this genotype on gray matter (GM) volume in cognitively unimpaired individuals has not yet been described.MethodsMulticenter brain magnetic resonance images (MRIs) from cognitively unimpaired ε2 homozygotes were matched (1:1) against all other APOE genotypes for relevant confounders (n = 223). GM volumes of ε2 genotypic groups were compared to each other and to the reference group (APOE ε3/ε3).ResultsCarrying at least one ε2 allele was associated with larger GM volumes in brain areas typically affected by AD and also in areas associated with cognitive resilience. APOE ε2 homozygotes, but not APOE ε2 heterozygotes, showed larger GM volumes in areas related to successful aging.DiscussionIn addition to the known resistance against amyloid‐β deposition, the larger GM volumes in key brain regions may confer APOE ε2 homozygotes additional protection against AD‐related cognitive decline.
Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03)
Gnant, Michael , Dueck, Amylou C. , Frantal, Sophie, Martín, Miguel , Burstein, H.J., Greil, Richard , Fox, Peter , Wolff, Antonio C. , Chan, Arlene , Winer, Eric P. , Pfeiler, Georg , Miller, Kathy D. , Suga, Jennifer M. , Rubovsky, Gabor, Bliss, Judith M. , Nowecki, Zbigniew , Hahn, Olwen, Thomson, Jacqui, Amillano, Kepa , Rugo, Hope S. , Steger, Guenther G. , Aranguiz, Blanca Hernando Fernández de , Haddad, Tufia C. , Perelló, Antonia , Bellet, Meritxell , Fohler, Hannes, Jallitsch-Halper, Anita, Solomon, Kadine, Schurmans, Céline , Theall, K. P., Lu, Dongrui R. , Tenner, Kathleen , Fesl, Christian , investigators, on behalf of the PALLAS groups and, Colleoni, Marco , Rubovsky, Gabor , Mayer, IA , Singer, Christian F , Nowecki, Zbigniew , Thomson, Jacqui , Rugo, Hope S , Hernando Fernández de Aránguiz, Blanca , Haddad, Tufia C , Metzger Filho, Otto , Schurmans, Céline , Lu, Dongrui R , Fesl, Christian , DeMichele, Angela , Mayer, Erica L , Dueck, A. C. , Wolff, Antonio C , Winer, Eric , Martin, Miguel , Gnant, Michael , Miller, Kathy D , Bliss, Judith , Colleoni, Marco , Mayer, Ingrid A. , Singer, Christian F. , Wolmark, Norman , Metzger, Otto , DeMichele, Angela , Mayer, Erica L. , investigators, on behalf of the PALLAS groups and

Mayo Clinic

Journal of Clinical Oncology | December 7, 2021 | Volume: 40 | Issue: 3 | Pages: 282-293

10.1200/jco.21.02554 | PMID 34874182 Get It

PURPOSE Palbociclib is a cyclin-dependent kinase 4 and 6 inhibitor approved for advanced breast cancer. In the adjuvant setting, the potential value of adding palbociclib to endocrine therapy for hormone receptor–positive breast cancer has not been confirmed. PATIENTS AND METHODS In the prospective, randomized, phase III PALLAS trial, patients with hormone receptor–positive, human epidermal growth factor receptor 2–negative early breast cancer were randomly assigned to receive 2 years of palbociclib (125 mg orally once daily, days 1-21 of a 28-day cycle) with adjuvant endocrine therapy or adjuvant endocrine therapy alone (for at least 5 years). The primary end point of the study was invasive disease-free survival (iDFS); secondary end points were invasive breast cancer–free survival, distant recurrence-free survival, locoregional cancer-free survival, and overall survival. RESULTS Among 5,796 patients enrolled at 406 centers in 21 countries worldwide over 3 years, 5,761 were included in the intention-to-treat population. At the final protocol-defined analysis, at a median follow-up of 31 months, iDFS events occurred in 253 of 2,884 (8.8%) patients who received palbociclib plus endocrine therapy and in 263 of 2,877 (9.1%) patients who received endocrine therapy alone, with similar results between the two treatment groups (iDFS at 4 years: 84.2% v 84.5%; hazard ratio, 0.96; CI, 0.81 to 1.14; P = .65). No significant differences were observed for secondary time-to-event end points, and subgroup analyses did not show any differences by subgroup. There were no new safety signals for palbociclib in this trial. CONCLUSION At this final analysis of the PALLAS trial, the addition of adjuvant palbociclib to standard endocrine therapy did not improve outcomes over endocrine therapy alone in patients with early hormone receptor–positive breast cancer.
Estimating Glomerular Filtration Rate from Serum Myo-Inositol, Valine, Creatinine and Cystatin C
Stämmler, Frank , Grassi, M , Meeusen, Jeffrey W. , Lieske, John C. , Dasari, Surendra , Dubourg, Laurence , Ehrich, J. H. H. , Schiffer, Eric, Lieske, John C , Grassi, Marcello , Lemoine, Sandrine

Mayo Clinic

Diagnostics | December 7, 2021 | Volume: 11 | Issue: 12 | Pages: 2291

10.3390/diagnostics11122291 | PMID 34943527 Get It

Assessment of renal function relies on the estimation of the glomerular filtration rate (eGFR). Existing eGFR equations, usually based on serum levels of creatinine and/or cystatin C, are not uniformly accurate across patient populations. In the present study, we expanded a recent proof-of-concept approach to optimize an eGFR equation targeting the adult population with and without chronic kidney disease (CKD), based on a nuclear magnetic resonance spectroscopy (NMR) derived ‘metabolite constellation’ (GFRNMR). A total of 1855 serum samples were partitioned into development, internal validation and external validation datasets. The new GFRNMR equation used serum myo-inositol, valine, creatinine and cystatin C plus age and sex. GFRNMR had a lower bias to tracer measured GFR (mGFR) than existing eGFR equations, with a median bias (95% confidence interval [CI]) of 0.0 (−1.0; 1.0) mL/min/1.73 m2 for GFRNMR vs. −6.0 (−7.0; −5.0) mL/min/1.73 m2 for the Chronic Kidney Disease Epidemiology Collaboration equation that combines creatinine and cystatin C (CKD-EPI2012) (p < 0.0001). Accuracy (95% CI) within 15% of mGFR (1-P15) was 38.8% (34.3; 42.5) for GFRNMR vs. 47.3% (43.2; 51.5) for CKD-EPI2012 (p < 0.010). Thus, GFRNMR holds promise as an alternative way to assess eGFR with superior accuracy in adult patients with and without CKD.
Socioeconomic and demographic factors in the diagnosis and treatment of Chiari malformation type I and syringomyelia
Akbari, Syed Hassan A., Rizvi, Asad A., CreveCoeur, Travis S., Han, Rowland H., Greenberg, Jacob K., Torner, James, Brockmeyer, Douglas L., Wellons, John C., Leonard, Jeffrey R., Mangano, Francesco T., Johnston, James M., Shah, Manish N., Iskandar, Bermans J., Ahmed, Raheel, Tuite, Gerald F., Kaufman, Bruce A., Daniels, David J., Jackson, Eric M., Grant, Gerald A., Powers, Alexander K., Couture, Daniel E., Adelson, P. David, Alden, Tord D., Aldana, Philipp R., Anderson, Richard C. E., Selden, Nathan R., Bierbrauer, Karin, Boydston, William, Chern, Joshua J., Whitehead, William E., Dauser, Robert C., Ellenbogen, Richard G., Ojemann, Jeffrey G., Fuchs, Herbert E., Guillaume, Daniel J., Hankinson, Todd C., O’Neill, Brent R., Iantosca, Mark, Oakes, W. Jerry, Keating, Robert F., Klimo, Paul, Muhlbauer, Michael S., McComb, J. Gordon, Menezes, Arnold H., Khan, Nickalus R., Niazi, Toba N., Ragheb, John, Shannon, Chevis N., Smith, Jodi L., Ackerman, Laurie L., Jea, Andrew H., Maher, Cormac O., Narayan, Prithvi, Albert, Gregory W., Stone, Scellig S. D., Baird, Lissa C., Gross, Naina L., Durham, Susan R., Greene, Stephanie, McKinstry, Robert C., Shimony, Joshua S., Strahle, Jennifer M., Smyth, Matthew D., Dacey, Ralph G., Park, Tae Sung, Limbrick, David D., Torner, James C. , Greene, Stephanie , Jackson, Eric M. , Stone, Scellig , Akbari, Syed Hassan A., Rizvi, Asad A., CreveCoeur, Travis S., Han, Rowland H., Greenberg, Jacob K., Brockmeyer, Douglas L., Wellons, John C., Leonard, Jeffrey R., Mangano, Francesco T., Johnston, James M., Shah, Manish N., Iskandar, Bermans J., Ahmed, Raheel, Tuite, Gerald F., Kaufman, Bruce A., Daniels, David J., Jackson, Eric M., Grant, Gerald A., Powers, Alexander K., Couture, Daniel E., Adelson, P. David, Alden, Tord D., Aldana, Philipp R., Anderson, Richard C. E., Selden, Nathan R., Bierbrauer, Karin, Boydston, William, Chern, Joshua J., Whitehead, William E., Dauser, Robert C., Ellenbogen, Richard G., Ojemann, Jeffrey G., Fuchs, Herbert E., Guillaume, Daniel J., Hankinson, Todd C., O’Neill, Brent R., Iantosca, Mark, Oakes, W. Jerry, Keating, Robert F., Klimo, Paul, Muhlbauer, Michael S., McComb, J. Gordon, Menezes, Arnold H., Khan, Nickalus R., Niazi, Toba N., Ragheb, John, Shannon, Chevis N., Smith, Jodi L., Ackerman, Laurie L., Jea, Andrew H., Maher, Cormac O., Narayan, Prithvi, Albert, Gregory W., Stone, Scellig S. D., Baird, Lissa C., Gross, Naina L., Durham, Susan R., Greene, Stephanie, McKinstry, Robert C., Shimony, Joshua S., Strahle, Jennifer M., Smyth, Matthew D., Dacey, Ralph G., Park, Tae Sung, Limbrick, David D.

Mayo Clinic

Journal of Neurosurgery: Pediatrics | December 3, 2021 | Volume: 29 | Issue: 3 | Pages: 288-297

10.3171/2021.9.peds2185 | PMID 34861643 Get It

OBJECTIVE The goal of this study was to assess the social determinants that influence access and outcomes for pediatric neurosurgical care for patients with Chiari malformation type I (CM-I) and syringomyelia (SM). METHODS The authors used retro- and prospective components of the Park-Reeves Syringomyelia Research Consortium database to identify pediatric patients with CM-I and SM who received surgical treatment and had at least 1 year of follow-up data. Race, ethnicity, and insurance status were used as comparators for preoperative, treatment, and postoperative characteristics and outcomes. RESULTS A total of 637 patients met inclusion criteria, and race or ethnicity data were available for 603 (94.7%) patients. A total of 463 (76.8%) were non-Hispanic White (NHW) and 140 (23.2%) were non-White. The non-White patients were older at diagnosis (p = 0.002) and were more likely to have an individualized education plan (p < 0.01). More non-White than NHW patients presented with cerebellar and cranial nerve deficits (i.e., gait ataxia [p = 0.028], nystagmus [p = 0.002], dysconjugate gaze [p = 0.03], hearing loss [p = 0.003], gait instability [p = 0.003], tremor [p = 0.021], or dysmetria [p < 0.001]). Non-White patients had higher rates of skull malformation (p = 0.004), platybasia (p = 0.002), and basilar invagination (p = 0.036). Non-White patients were more likely to be treated at low-volume centers than at high-volume centers (38.7% vs 15.2%; p < 0.01). Non-White patients were older at the time of surgery (p = 0.001) and had longer operative times (p < 0.001), higher estimated blood loss (p < 0.001), and a longer hospital stay (p = 0.04). There were no major group differences in terms of treatments performed or complications. The majority of subjects used private insurance (440, 71.5%), whereas 175 (28.5%) were using Medicaid or self-pay. Private insurance was used in 42.2% of non-White patients compared to 79.8% of NHW patients (p < 0.01). There were no major differences in presentation, treatment, or outcome between insurance groups. In multivariate modeling, non-White patients were more likely to present at an older age after controlling for sex and insurance status (p < 0.01). Non-White and male patients had a longer duration of symptoms before reaching diagnosis (p = 0.033 and 0.004, respectively). CONCLUSIONS Socioeconomic and demographic factors appear to influence the presentation and management of patients with CM-I and SM. Race is associated with age and timing of diagnosis as well as operating room time, estimated blood loss, and length of hospital stay. This exploration of socioeconomic and demographic barriers to care will be useful in understanding how to improve access to pediatric neurosurgical care for patients with CM-I and SM.
Different rates of cognitive decline in autosomal dominant and late‐onset Alzheimer disease
Buckles, Virginia, Xiong, Chengjie , Bateman, Randall J. , Hassenstab, Jason , Berman, Sarah , Chhatwal, Jasmeer P. , Fagan, Anne M. , Goate, Alison , Graff‐Radford, Neill R. , Marcus, Daniel S., Masters, Colin L. , McCue, Lena , Mori, Hiroshi , Moulder, Krista L., Noble, James M. , Paumier, Katrina L. , Preische, Oliver, Ringman, John M. , Fox, Nick C. , Salloway, Stephen , Vöglein, Jonathan , Morris, John C. , Network, for the Dominantly Inherited Alzheimer's, Bateman, Randall J , Masters, Colin L , Vöglein, Jonathan , Xiong, Chengjie , Fox, Nick C , Hassenstab, Jason , Morris, John C , Goate, Alison M , Berman, Sarah , Xiong, Chengjie , Allegri, Ricardo , Danek, Adrian , Ghetti, Bernardino , Jucker, Mathias , McDade, Eric , Schofield, Peter R. , Martins, Ralph N. , Network, for the Dominantly Inherited Alzheimer's, Noble, James M

Mayo Clinic

Alzheimer's & Dementia | December 2, 2021 | Volume: 18 | Issue: 10 | Pages: 1754-1764

10.1002/alz.12505 | PMID 34854530 Get It

AbstractAs prevention trials advance with autosomal dominant Alzheimer disease (ADAD) participants, understanding the similarities and differences between ADAD and “sporadic” late‐onset AD (LOAD) is critical to determine generalizability of findings between these cohorts. Cognitive trajectories of ADAD mutation carriers (MCs) and autopsy‐confirmed LOAD individuals were compared to address this question. Longitudinal rates of change on cognitive measures were compared in ADAD MCs (n = 310) and autopsy‐confirmed LOAD participants (n = 163) before and after symptom onset (estimated/observed). LOAD participants declined more rapidly in the presymptomatic (preclinical) period and performed more poorly at symptom onset than ADAD participants on a cognitive composite. After symptom onset, however, the younger ADAD MCs declined more rapidly. The similar but not identical cognitive trajectories (declining but at different rates) for ADAD and LOAD suggest common AD pathologies but with some differences.
ChAdOx1 interacts with CAR and PF4 with implications for thrombosis with thrombocytopenia syndrome
Baker, Alexander T. , Boyd, Ryan J. , Sarkar, Daipayan , Teijeira, Alicia , Chan, Chun Kit , Bates, Emily A. , Waraich, Kasim , Vant, John , Wilson, Eric , Truong, Chloe D. , Lipka‐Lloyd, Magdalena , Fromme, Petra , Vermaas, Josh V. , Williams, Dewight , Machiesky, LeeAnn , Nagalo, Bolni Marius , Coughlan, Lynda , Umlauf, Scott , Rizkallah, P.J. , Parker, Alan L. , Bates, Emily , Vermaas, Josh , Heurich, Meike , Nagalo, Bolni M, Coughlan, Lynda , Umlauf, Scott , Chiu, Po-Lin , Rizkallah, Pierre J , Cohen, Taylor S , Parker, Alan L , Singharoy, Abhishek , Borad, Mitesh J , Vant, John W , Fromme, Petra , Nagalo, Bolni , Baker, Alexander , Singharoy, Abhishek , Borad, Mitesh J. , Sarkar, Daipayan

Mayo Clinic

Science Advances | December 1, 2021 | Volume: 7 | Issue: 49 | Pages: No page available

10.1126/sciadv.abl8213 | PMID 34851659 Get It

We observe previously unknown interactions between clinically important adenovirus vector capsids, platelet factor 4, and CAR.
A Man with Exertional Dyspnea and Diffuse Bronchial Wall Thickening
Stultz, Benjamin R. , Ryu, Jay H. , Edell, Eric S., Kelm, Diana J. , Ryu, Jay H , Stultz, Benjamin R. , Edell, Eric S., Kelm, Diana J

Mayo Clinic

Annals of the American Thoracic Society | December 1, 2021 | Volume: 18 | Issue: 12 | Pages: 2084-2089

10.1513/annalsats.202105-545cc | PMID 34851243 Get It

Clinical Trial Endpoints in Metastatic Cancer: Using Individual Participant Data to Inform Future Trials Methodology
Goldberg, Richard M. , Adams, Richard , Buyse, Marc , Eng, Cathy , Grothey, Axel , André, Thierry , Sobrero, Alberto , Lichtman, Stuart M. , Benson, Al B. , Punt, Cornelis J.A. , Maughan, Tim , Sommeijer, Dirkje W. , Saad, Everardo D. , Shi, Qian , Coart, Elisabeth , Chibaudel, Benoist , Koopman, Miriam , Schmoll, Hans‐Joachim , Taı̈eb, Julien , Matheson, Alastair , Gramont, Aimery de , Burzykowski, Tomasz , Saad, Everardo D , Shi, Qian , Koopman, Miriam , Schmoll, Hans-Joachim , Taieb, Julien , Tebbutt, Niall C , Zalcberg, John , Tabernero, Josep , Van Cutsem, Eric , De Gramont, Aimery , André, Thierry , Maughan, Timothy S , Lichtman, Stuart M , Adams, Richard , Buyse, Marc E , Eng, Cathy , Chibaudel, Benoist , Burzykowski, Tomasz , Yoshino, Takayuki , Tebbutt, Niall C. , Zalcberg, John , Tabernero, Josep , Cutsem, Eric Van

Mayo Clinic

JNCI: Journal of the National Cancer Institute | November 30, 2021 | Volume: 114 | Issue: 6 | Pages: 819-828

10.1093/jnci/djab218 | PMID 34865086 Get It

Abstract Meta-analysis based on individual participant data (IPD) is a powerful methodology for synthesizing evidence by combining information drawn from multiple trials. Hitherto, its principal application has been in questions of clinical management, but an increasingly important use is in clarifying trials methodology, for instance in the selection of endpoints, as discussed in this review. In oncology, the Aide et Recherche en Cancérologie Digestive (ARCAD) Metastatic Colorectal Cancer Database is a leader in the use of IPD-based meta-analysis in methodological research. The ARCAD database contains IPD from more than 38 000 patients enrolled in 46 studies and continues to collect phase III trial data. Here, we review the principal findings of the ARCAD project in respect of endpoint selection and examine their implications for cancer trials. Analysis of the database has confirmed that progression-free survival (PFS) is no longer a valid surrogate endpoint predictive of overall survival in the first-line treatment of colorectal cancer. Nonetheless, PFS remains an endpoint of choice for most first-line trials in metastatic colorectal cancer and other solid tumors. Only substantial PFS effects are likely to translate into clinically meaningful benefits, and accordingly, we advocate an oncology research model designed to identify highly effective treatments in carefully defined patient groups. We also review the use of the ARCAD database in assessing clinical response including novel response metrics and prognostic markers. These studies demonstrate the value of IPD as a tool for methodological studies and provide a reference point for the expansion of this approach within clinical cancer research.
The Outpatient Approach to Dizziness
Brune, Anthony J., Eggenberger, Eric , Eggenberger, Eric R

Mayo Clinic

Seminars in Neurology | November 26, 2021 | Volume: 41 | Issue: 06 | Pages: 771-780

10.1055/s-0041-1726369 | PMID 34826878 Get It

AbstractThe evaluation of the dizzy patient is complicated by many common pitfalls. The patient's description of symptoms and the standard neurologic examination are often nonspecific or unrevealing, and neuroimaging is most often normal. Over the past several years, research has demonstrated that a refocusing of history taking results in more reliable and diagnostically helpful information. This can guide a targeted expansion of the exam, often with an emphasis on eye movements.